𝔖 Bobbio Scriptorium
✦   LIBER   ✦

78 Imatinib Treatment for Patients With Advanced Stage Hepatocellular Carcinoma: A Multicenter Phase II Trial

✍ Scribed by Graziadei, Ivo; Finkenstedt, Armin; Stauber, Rudolf E.; Müller, Christian; Trauner, Michael; Vogel, Wolfgang

Book ID
121948620
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
100 KB
Volume
138
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of gemcitabine in patie
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
✍ Charles S. Fuchs; Jeffrey W. Clark; David P. Ryan; Mathew H. Kulke; Haesook Kim; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract ## BACKGROUND There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerabili

A Phase II trial of nolatrexed dihydroch
A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma
✍ Keith Stuart; Judy Tessitore; Jeff Rudy; Neil Clendennin; Amanda Johnston 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

## BACKGROUND. Inoperable hepatocellular carcinoma is an incurable malignancy with no accepted standard therapy. Chemotherapy has demonstrated occasional responses and the need is great for a new and effective agent. Therefore the authors conducted this Phase II trial of a novel thymidylate syntha

Thalidomide in the treatment of patients
Thalidomide in the treatment of patients with hepatocellular carcinoma : A Phase II trial
✍ Yehuda Z. Patt; Manal M. Hassan; Richard D. Lozano; Ajay K. Nooka; Isaac I. Schn 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

## Abstract ## BACKGROUND The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents. However, the abundant vascularity of HCC presents an attractive target for antiangiogenic therapy that pote

A randomized multicenter phase II clinic
A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma
✍ Qinghua Zhou; Xun Sun; Lingyuan Zeng; Jie Liu; Zhirong Zhang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 151 KB

## From the clinical editor: Intravenous administration of mitoxantrone-loaded polybutylcyanacrylate nanoparticles (dhad-pbca-nps) allows increased cytotoxicity in hepatic tumors and prolonged the median survival periods to 5.46 months compared to 3.23 months in controls.